SYGNIS obtains European and American patent for an innovative platform of very versatile and effective analysis of medicinal products.
SYGNIS obtains European and American patent for an innovative platform of very versatile and effective drugs analysis. -patents cover a new procedure for the analysis of drugs in development stage, based on the detection of protein-protein interactions -Detection of interactions protein has become an increasingly important method for the development of new drugs, because it simplifies testing and allows to analyze new drugs in a way absolutely innovative -the new technology of SYGNIS extends the possibilities of innovative drugs with new mechanisms of action -SYGNIS intends to award to another firm the license for the distribution of this technology -SYGNIS completed its merger with the Spanish company X-Pol, a subsidiary of the GENETRIX group, in December of last year Heidelberg, Madrid, January of 2013- the signing of biotechnology SYGNIS Pharma AG (Frankfurt: LIO1;) ISIN: DE000A1RFM03; Prime Standard) has obtained patents for Europe and the United States of a new technology for the detection of interactions between proteins, a novel platform of analysis for the development of new drugs. According to the CEO of SYGNIS, Pilar de la Huerta, we’ll give another signing the license for the distribution of this technology, and we hope our first revenue linked to this platform during the present fiscal year ”. The study of protein-protein interactions belongs to the field of proteomics, becoming increasingly important in the investigation of new custom drugs. The new...
Read More